UK markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.46000.0000 (0.00%)
At close: 04:00PM EDT
1.4700 +0.01 (+0.68%)
After hours: 07:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.4600
Open1.4600
Bid1.4400 x 1200
Ask1.5100 x 200
Day's range1.4300 - 1.5200
52-week range0.6200 - 2.3100
Volume841,263
Avg. volume1,926,690
Market cap183.605M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.2400
Earnings date12 Aug 2024 - 16 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.33
  • Zacks

    Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?

    Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • GlobeNewswire

    Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

    SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person

  • GlobeNewswire

    Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

    Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Ato